LDLR and melanoma: Upon examining the ability of PCSK9 to act on LRP-1 in B16F1/F10 melanoma cells (Figure 2), we discovered that PCSK9 is capable of enhancing LRP-1 degradation in both the B16F1 and the more metastatic B16F10 cells, but only the more active GOF PCSK9D374Y is capable of acting on the LDLR in B16F10, and not in B16F1 cells.